A Study Comparing Tazarotene Cream 0.05% to TAZORAC® (Tazarotene) Cream 0.05% and Both to a Placebo Control in the Treatment of Plaque Psoriasis
Phase 3
Completed
- Conditions
- Plaque Psoriasis
- Interventions
- First Posted Date
- 2016-09-01
- Last Posted Date
- 2018-08-29
- Lead Sponsor
- Fougera Pharmaceuticals Inc.
- Target Recruit Count
- 855
- Registration Number
- NCT02886702
- Locations
- 🇺🇸
Fougera Investigational Site, San Antonio, Texas, United States
A Study Comparing Tazarotene Cream 0.1% to TAZORAC® (Tazarotene) Cream 0.1% and Both to a Placebo Control in the Treatment of Acne Vulgaris
Phase 3
Completed
- Conditions
- Acne Vulgaris
- Interventions
- First Posted Date
- 2016-09-01
- Last Posted Date
- 2018-08-17
- Lead Sponsor
- Fougera Pharmaceuticals Inc.
- Target Recruit Count
- 1110
- Registration Number
- NCT02886715
- Locations
- 🇺🇸
Fougera Investigational Site, Austin, Texas, United States
Study Comparing Product 0405 to a Vehicle Control in the Treatment of Mild to Moderate Atopic Dermatitis in Pediatric Subjects
Phase 3
Withdrawn
- Conditions
- Atopic Dermatitis
- Interventions
- Drug: Product 0405Drug: Placebo for Product 0405
- First Posted Date
- 2014-06-27
- Last Posted Date
- 2014-06-27
- Lead Sponsor
- Fougera Pharmaceuticals Inc.
- Registration Number
- NCT02176538
Study to Determine the Pharmacokinetics of Product 0405
Phase 3
Withdrawn
- Conditions
- Atopic Dermatitis
- Interventions
- Drug: Product 0405
- First Posted Date
- 2014-06-27
- Last Posted Date
- 2014-06-27
- Lead Sponsor
- Fougera Pharmaceuticals Inc.
- Registration Number
- NCT02176577
Study Comparing Product 0405 to a Vehicle Control in the Treatment of Mild to Moderate Atopic Dermatitis in Pediatric Subjects
Phase 3
Withdrawn
- Conditions
- Atopic Dermatitis
- Interventions
- Drug: Placebo for Product 0405Drug: Product 0405
- First Posted Date
- 2014-06-27
- Last Posted Date
- 2014-06-27
- Lead Sponsor
- Fougera Pharmaceuticals Inc.
- Registration Number
- NCT02176551
Safety Study Evaluating the Adrenal Suppression Potential of Product 0405 in Pediatric Subjects With Atopic Dermatitis
Phase 2
Completed
- Conditions
- Atopic Dermatitis
- Interventions
- Drug: Product 0405
- First Posted Date
- 2010-11-02
- Last Posted Date
- 2012-04-11
- Lead Sponsor
- Fougera Pharmaceuticals Inc.
- Target Recruit Count
- 114
- Registration Number
- NCT01232543
- Locations
- 🇺🇸
Fougera Pharmaceuticals Inc., Melville, New York, United States
Study of 0417 Ointment in the Treatment of Atopic Dermatitis
Phase 3
Completed
- Conditions
- Atopic Dermatitis
- Interventions
- First Posted Date
- 2010-06-08
- Last Posted Date
- 2014-10-09
- Lead Sponsor
- Fougera Pharmaceuticals Inc.
- Target Recruit Count
- 899
- Registration Number
- NCT01139450
- Locations
- 🇺🇸
Fougera Pharmaceuticals Inc., Melville, New York, United States
Study to Evaluate Effect of Pandel Cream 0.1% on HPA Axis in Pediatric and Adult Population
- First Posted Date
- 2010-06-04
- Last Posted Date
- 2016-05-04
- Lead Sponsor
- Fougera Pharmaceuticals Inc.
- Target Recruit Count
- 19
- Registration Number
- NCT01137032
- Locations
- 🇺🇸
Christopher Huerter, MD, Omaha, Nebraska, United States
🇺🇸Oswald Mikell, MD, Hilton Head Island, South Carolina, United States
🇺🇸Michael Gold, MD, Nashville, Tennessee, United States
Study of 0416 Ointment in the Treatment of Atopic Dermatitis
Phase 3
Completed
- Conditions
- Atopic Dermatitis
- Interventions
- First Posted Date
- 2010-01-21
- Last Posted Date
- 2014-10-03
- Lead Sponsor
- Fougera Pharmaceuticals Inc.
- Target Recruit Count
- 793
- Registration Number
- NCT01053247
- Locations
- 🇺🇸
Fougera Pharmaceuticals Inc., Melville, New York, United States
Study of 0444 Gel in the Treatment of Inflammatory Lesions of Rosacea
Phase 3
Completed
- Conditions
- Inflammatory Rosacea
- Interventions
- Drug: 0444
- First Posted Date
- 2009-11-19
- Last Posted Date
- 2014-07-04
- Lead Sponsor
- Fougera Pharmaceuticals Inc.
- Target Recruit Count
- 867
- Registration Number
- NCT01016782
© Copyright 2025. All Rights Reserved by MedPath